Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Oral Oncol. 2024 Nov;158:106981. doi: 10.1016/j.oraloncology.2024.106981. Epub 2024 Aug 13.
To evaluate the effectiveness and safety of low-dose gemcitabine and metronomic capecitabine in combination with tislelizumab for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who have previously received other anti-PD-1 therapies.
This retrospective, observational study included patients with RM-NPC who had prior treatment with anti-PD-1 therapy and subsequently received tislelizumab along with low-dose gemcitabine and metronomic capecitabine between March 2019 and August 2023. Progression-free survival (PFS) was estimated using the Kaplan-Meier method.
Among 25 eligible patients, 8 (20%) achieved a complete response (CR). The objective response rate (ORR) was 68%, and the disease control rate (DCR) was 80%. The 1-year PFS rate was 78%. All patients experienced treatment-related adverse events, which were all grade 1 or 2.
The combination of tislelizumab with low-dose gemcitabine and metronomic capecitabine demonstrated promising antitumor effectiveness in RM-NPC patients who had failed previous anti-PD-1 therapy, with a manageable safety profile.
评估低剂量吉西他滨和卡培他滨节拍疗法联合替雷利珠单抗治疗既往接受过其他抗 PD-1 治疗的复发性或转移性鼻咽癌（RM-NPC）患者的有效性和安全性。
这是一项回顾性、观察性研究，纳入了 2019 年 3 月至 2023 年 8 月期间接受过抗 PD-1 治疗且随后接受替雷利珠单抗联合低剂量吉西他滨和卡培他滨节拍疗法治疗的 RM-NPC 患者。采用 Kaplan-Meier 法估计无进展生存期（PFS）。
在 25 名符合条件的患者中，8 名（20%）患者达到完全缓解（CR）。客观缓解率（ORR）为 68%，疾病控制率（DCR）为 80%。1 年 PFS 率为 78%。所有患者均发生治疗相关不良事件，均为 1 级或 2 级。
替雷利珠单抗联合低剂量吉西他滨和卡培他滨节拍疗法在既往抗 PD-1 治疗失败的 RM-NPC 患者中显示出有前景的抗肿瘤疗效，且安全性可管理。
